- Details
- Description
-
Packaging Size20t
-
Strength55mg
-
CompositonAumolertinib
-
Treatmentadvanced NSCLC and an EGFR T790M mutation
-
FormTablet
-
BrandAmeile (阿美乐)
-
Quantity Unit55mg*20t
-
ManufacturerHANSOH Pharma,china
About Aumolertinib
Aumolertinib (previously known as almonertinib) is a EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Aumolertinib sold under the brand name Ameile.
- Aumolertinib sold under the brand name 阿美乐 in china.
Approval
In March 2020 aumolertinib was approved in China, on the basis of APOLLO (ClinicalTrials.gov identifier: NCT0298110), for the treatment of patients with advanced NSCLC and an EGFR T790M mutation.
Dosage
The recommended dose of this product is 110 mg, taken orally once a day until disease progression or intolerable toxicity occurs.
This product can be taken on an empty stomach or after meals. It is recommended to take it at approximately the same time every day, swallow the whole tablet, and take it with a full glass of water, without chewing or crushing. If you miss a dose of this product, if the next dose is more than 12 hours away, you should take this product.
Dosage adjustment
Depending on the safety and tolerability of the individual patient, the drug can be suspended or reduced. If a dose reduction is required, the dose should be reduced to 55 mg once a day.
